Cited by CrossRef (12)

  1. José M. González-Clemente, María García-Castillo, Juan J. Gorgojo-Martínez, Alberto Jiménez, Ignacio Llorente, Eduardo Matute, Cristina Tejera, Aitziber Izarra, Albert Lecube. Beyond the Glycaemic Control of Dapagliflozin: Impact on Arterial Stiffness and Macroangiopathy. Diabetes Ther 2022;13:1281
    https://doi.org/10.1007/s13300-022-01280-6
  2. Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, Anna Di Martino, Gaetana Albanese, Erica Vetrano, Celestino Sardu, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso. Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines 2021;9:1356
    https://doi.org/10.3390/biomedicines9101356
  3. Adam J. Nelson, Josephine L. Harrington, Ahmed A. Kolkailah, Neha J. Pagidipati, Darren K. McGuire. Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. Heart Failure Clinics 2022;18:597
    https://doi.org/10.1016/j.hfc.2022.03.007
  4. R. Rajasekar, Sivaraj Mohana Sundaram, C. Poornima Raj, M. Poovitha, Janardanan Subramonia Kumar. Analysing uric acid levels to assess the effectiveness of dapagliflozin. Clinical Nutrition ESPEN 2024;59:81
    https://doi.org/10.1016/j.clnesp.2023.11.013
  5. Bo Kyung Koo. Letter: Effects of 6 Months of Dapagliflozin Treatment on Metabolic Profile and Endothelial Cell Dysfunction for Obese Type 2 Diabetes Mellitus Patients without Atherosclerotic Cardiovascular Disease (J Obes Metab Syndr 2020;29:215-21). Journal of Obesity & Metabolic Syndrome 2021;30:72
    https://doi.org/10.7570/jomes20133
  6. Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee. Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study. Diabetes Obesity Metabolism 2023;25:2743
    https://doi.org/10.1111/dom.15164
  7. Dimitrios Patoulias, Christodoulos Papadopoulos, Ioanna Zografou, Alexandra Katsimardou, Asterios Karagiannis, Michael Doumas. Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study. Medicina 2022;58:1167
    https://doi.org/10.3390/medicina58091167
  8. Roberto Castelli, Antonio Gidaro, Gavino Casu, Pierluigi Merella, Nicia I. Profili, Mattia Donadoni, Margherita Maioli, Alessandro P. Delitala. Aging of the Arterial System. IJMS 2023;24:6910
    https://doi.org/10.3390/ijms24086910
  9. Neda Shakour, Shima Karami, Mehrdad Iranshahi, Alexandra E. Butler, Amirhossein Sahebkar. Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2024;18:102934
    https://doi.org/10.1016/j.dsx.2023.102934
  10. Joon Ho Moon, Soo Lim. Pharmacotherapy for patients with diabetes mellitus. J Korean Med Assoc 2020;63:766
    https://doi.org/10.5124/jkma.2020.63.12.766
  11. Giovanni Battista Bonfioli, Luca Rodella, Roberta Rosati, Alberto Carrozza, Marco Metra, Enrico Vizzardi. Aortopathies: From Etiology to the Role of Arterial Stiffness. JCM 2023;12:3949
    https://doi.org/10.3390/jcm12123949
  12. Panagiotis Stachteas, Paschalis Karakasis, Dimitrios Patoulias, Francesco Clemenza, Nikolaos Fragakis, Manfredi Rizzo. The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis. Annals of Medicine 2023;55
    https://doi.org/10.1080/07853890.2024.2304667